Last checked at 17 Oct 2023 07:01
Destiny Pharma plc
("Destiny Pharma" or "the Company")
XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73
Brighton, United Kingdom - 17 October 2023 - Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, confirms that it is hosting a meeting for analysts and investors on its XF product pipeline later today at 2:00pm BST / 9:00am EDT.
The meeting will feature updates from Destiny Pharma leadership and presentations from leading experts, as well as an interview with a UK patient.
Leadership updates will detail the commercial opportunity for XF-73 nasal, including an analysis of the addressable market, and updates on the XF platform, pipeline and potential, including new microbiological data demonstrating the effectiveness of XF-73 against all known antibiotic strains of Staphylococcus.
Leading experts will give the following presentations and discussions:
· Professor Mark Wilcox, consultant microbiologist and head of R&D in microbiology at the Leeds Teaching Hospital, and Richard Proctor, Professor Emeritus of Medicine and Medical Microbiology and Immunology at the University of Wisconsin-Madison, will present the issue of surgical site infections and their impact on healthcare systems
· Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD Anderson Cancer Center and Mr Raghbir Khakha, Consultant Trauma and Orthopaedic Surgeon at Guy's and St Thomas's Hospital will present the reality on the wards
The meeting will also include an interview with a UK patient who became infected with Staph. aureus following surgery for a torn anterior cruciate ligament.
Commenting on the event, Chris Tovey, Chief Executive Officer, Destiny Pharma, said:
"The potential of XF-73 nasal is one of the reasons I was motivated to join Destiny Pharma in its mission to reduce the emergence and impact of drug resistant pathogens with preventative solutions.
"The innovative XF platform includes a blockbuster, $2bn plus opportunity in the US alone, but has also shown utility beyond surgical site infections to address fungal and dermal infections as well. Most importantly, it has the potential to play an essential role in protecting vulnerable patients, and in doing so, save lives."
The meeting will be held in person at the offices of Cavendish, 1 Bartholomew Close, London, EC1A 7BL, alongside the option of virtual attendance via the Investor Meet platform. Prior registration for the event is required. To attend in person please contact RD@destinypharma.com.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.